AUSTIN, Texas and DURHAM, N.C., June 5, 2026

Shattuck Labs announced that it will host an investor call and webcast on June 8, 2026, to present comprehensive Phase 1 clinical data for SL-325, its potential first-in-class DR3-blocking antibody being developed for inflammatory and immune-mediated diseases. The presentation will include detailed results covering safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic activity, and immunogenicity, along with an update on the company’s broader pipeline.

Phase 1 Clinical Results and Pipeline Update

The webcast will feature members of Shattuck’s executive and clinical leadership team, including Chief Executive Officer Taylor Schreiber, Chief Medical Officer Lini Pandite, Chief Scientific Officer Suresh De Silva, Vice President of Clinical Development Michael Choi, and Chief Financial Officer Andrew Neill. Management is expected to discuss the full Phase 1 dataset and provide strategic updates on ongoing and future development programs.

SL-325 Targets the DR3/TL1A Pathway

SL-325 is a fully human, Fc-silenced monoclonal antibody designed to block Death Receptor 3 (DR3) and achieve complete inhibition of the clinically validated DR3/TL1A inflammatory pathway. According to preclinical studies, the antibody demonstrated high-affinity receptor binding and stronger pathway inhibition compared with therapies targeting the TL1A ligand. The program is being advanced as a potential first-in-class treatment option for a range of immune-mediated disorders where excessive DR3 signaling contributes to chronic inflammation.

Advertisement

cGxPJobs Banner

Advancing Development in Immune-Mediated Diseases

The ongoing Phase 1 study is evaluating the safety and biological activity of SL-325 following encouraging preclinical findings, including a favorable safety profile in non-human primates. The upcoming presentation represents an important milestone for Shattuck as it seeks to validate DR3 blockade as a differentiated therapeutic approach and determine the next stages of clinical development. Investors and industry observers will be watching closely for evidence supporting advancement into later-stage studies.

Source: Shattuck Labs press release